Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
NanoString Technologies, Inc is a biotechnology business based in the US. NanoString Technologies shares (NSTG) are listed on the NASDAQ and all prices are listed in US Dollars. NanoString Technologies employs 551 staff and has a trailing 12-month revenue of around USD$118 million.
|52-week range||USD$13.85 - USD$86.42|
|50-day moving average||USD$73.3739|
|200-day moving average||USD$53.453|
|Wall St. target price||USD$68.6|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.504|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$118 million|
|Gross profit TTM||USD$81.5 million|
|Return on assets TTM||-20.71%|
|Return on equity TTM||-72.02%|
|Market capitalisation||USD$3.3 billion|
TTM: trailing 12 months
There are currently 3.8 million NanoString Technologies shares held short by investors – that's known as NanoString Technologies's "short interest". This figure is 1.6% up from 3.7 million last month.
There are a few different ways that this level of interest in shorting NanoString Technologies shares can be evaluated.
NanoString Technologies's "short interest ratio" (SIR) is the quantity of NanoString Technologies shares currently shorted divided by the average quantity of NanoString Technologies shares traded daily (recently around 752101.79282869). NanoString Technologies's SIR currently stands at 5.02. In other words for every 100,000 NanoString Technologies shares traded daily on the market, roughly 5020 shares are currently held short.
However NanoString Technologies's short interest can also be evaluated against the total number of NanoString Technologies shares, or, against the total number of tradable NanoString Technologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NanoString Technologies's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 NanoString Technologies shares in existence, roughly 90 shares are currently held short) or 0.1054% of the tradable shares (for every 100,000 tradable NanoString Technologies shares, roughly 105 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NanoString Technologies.
Find out more about how you can short NanoString Technologies stock.
We're not expecting NanoString Technologies to pay a dividend over the next 12 months.
Over the last 12 months, NanoString Technologies's shares have ranged in value from as little as $13.85 up to $86.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NanoString Technologies's is 1.7465. This would suggest that NanoString Technologies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and pan cancer and 360 gene expression, CAR-T characterization, neuropathology and neuro-inflammation gene expression, autoimmune disease gene expression, miRNA expression, human organ transplant, human and mouse metabolic pathway, and human and mouse fibrosis panels. Further, the company offers nCounter based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics; and Hyb & Seq molecular profiling system to determine and analyze gene sequences within biological samples. It has collaboration with Celgene Corporation; Merck & Co., Inc.; Medivation, Inc.; Astellas Pharma, Inc.; and Oregon Health & Science University for the development of novel GeoMx® Digital Spatial Profiler protein assays to spatially profile breast cancer. NanoString Technologies, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.